{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:38:09Z","timestamp":1789562289643,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.cld.2018.03.007","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T23:35:05Z","timestamp":1530747305000},"page":"563-578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era"],"prefix":"10.1016","volume":"22","author":[{"given":"Aparna","family":"Goel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woong Ray","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cld.2018.03.007_bib1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2018.03.007_bib2","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"9777","key":"10.1016\/j.cld.2018.03.007_bib3","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","article-title":"Primary biliary cirrhosis","volume":"377","author":"Selmi","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cld.2018.03.007_bib4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0016-5085(80)90571-5","article-title":"Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients","volume":"78","author":"Christensen","year":"1980","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2018.03.007_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hep.510230108","article-title":"Time course of histological progression in primary biliary cirrhosis","volume":"23","author":"Locke","year":"1996","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2018.03.007_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1572-0241.1999.00770.x","article-title":"Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis","volume":"94","author":"Springer","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2018.03.007_bib7","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2018.03.007_bib8","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S2210-7401(12)70015-3","article-title":"Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action","volume":"36","author":"Poupon","year":"2012","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"8537","key":"10.1016\/j.cld.2018.03.007_bib9","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0140-6736(87)91610-2","article-title":"Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?","volume":"1","author":"Poupon","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2018.03.007_bib10","doi-asserted-by":"crossref","unstructured":"Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. In: Gluud C, editor. Cochrane database of systematic reviews. Chichester (United Kingdom): John Wiley & Sons, Ltd; 2001. CD000551. https:\/\/doi.org\/10.1002\/14651858.CD000551.","DOI":"10.1002\/14651858.CD000551"},{"issue":"8","key":"10.1016\/j.cld.2018.03.007_bib11","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1572-0241.2002.05923.x","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial","volume":"97","author":"Papatheodoridis","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"9184","key":"10.1016\/j.cld.2018.03.007_bib12","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis","volume":"354","author":"Goulis","year":"1999","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cld.2018.03.007_bib13","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1572-0241.2006.00634.x","article-title":"Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials","volume":"101","author":"Shi","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2018.03.007_bib14","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2018.03.007_bib15","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Par\u00e9s","year":"2006","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2018.03.007_bib16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.26322","article-title":"Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study","volume":"58","author":"Zhang","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2018.03.007_bib17","first-page":"1148","article-title":"Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?","volume":"23","author":"Kilmurry","year":"1996","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2018.03.007_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"issue":"9","key":"10.1016\/j.cld.2018.03.007_bib19","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/j.1572-0241.2006.00699.x","article-title":"Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients","volume":"101","author":"ter Borg","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2018.03.007_bib20","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/hep.510290603","article-title":"Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC study group","volume":"29","author":"Poupon","year":"1999","journal-title":"Hepatology"},{"issue":"7\u20138","key":"10.1016\/j.cld.2018.03.007_bib21","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1023\/B:DDAS.0000037811.48575.da","article-title":"Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment","volume":"49","author":"Koulentaki","year":"2004","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.cld.2018.03.007_bib22","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1053\/he.2000.5852","article-title":"A\u00a0model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts","volume":"31","author":"Malinchoc","year":"2000","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2018.03.007_bib23","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/tri.12877","article-title":"Primary biliary cirrhosis has high wait-list mortality among patients listed for liver transplantation","volume":"30","author":"Singal","year":"2017","journal-title":"Transpl Int"},{"issue":"6","key":"10.1016\/j.cld.2018.03.007_bib24","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2014.01.029","article-title":"Optimising risk stratification in primary biliary cirrhosis: AST\/platelet ratio index predicts outcome independent of ursodeoxycholic acid response","volume":"60","author":"Trivedi","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2018.03.007_bib25","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/jgh.12938","article-title":"New simple prognostic score for primary biliary cirrhosis: albumin-bilirubin score","volume":"30","author":"Chan","year":"2015","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2018.03.007_bib26","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2018.03.007_bib27","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.13927","article-title":"The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210","volume":"45","author":"Yang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2018.03.007_bib28","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2018.03.007_bib29","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/0016-5085(85)90213-6","article-title":"Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial","volume":"89","author":"Christensen","year":"1985","journal-title":"Gastroenterology"},{"issue":"8688","key":"10.1016\/j.cld.2018.03.007_bib30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0140-6736(90)90734-M","article-title":"Use of prognostic models for assessment of value of liver transplantation in primary biliary cirrhosis","volume":"335","author":"Bonsel","year":"1990","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cld.2018.03.007_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making","volume":"10","author":"Dickson","year":"1989","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2018.03.007_bib32","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/0016-5085(93)91086-W","article-title":"Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. PBC1 and PBC2 trial groups","volume":"105","author":"Christensen","year":"1993","journal-title":"Gastroenterology"},{"issue":"1 Pt 1","key":"10.1016\/j.cld.2018.03.007_bib33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/hep.1840200120","article-title":"Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits","volume":"20","author":"Murtaugh","year":"1994","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2018.03.007_bib34","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1053\/jlts.2000.6503","article-title":"Adaptation of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidates","volume":"6","author":"Kim","year":"2000","journal-title":"Liver Transpl"},{"issue":"5","key":"10.1016\/j.cld.2018.03.007_bib35","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/0016-5085(89)91698-3","article-title":"Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial","volume":"97","author":"Leuschner","year":"1989","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1016\/j.cld.2018.03.007_bib36","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis","volume":"324","author":"Poupon","year":"1991","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cld.2018.03.007_bib37","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0168-8278(05)80214-4","article-title":"Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC","volume":"17","author":"Battezzati","year":"1993","journal-title":"J Hepatol"},{"issue":"19","key":"10.1016\/j.cld.2018.03.007_bib38","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group","volume":"330","author":"Poupon","year":"1994","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2018.03.007_bib39","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1440-1746.1994.tb01237.x","article-title":"A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis","volume":"9","author":"Turner","year":"1994","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2018.03.007_bib40","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2018.03.007_bib41","first-page":"759","article-title":"A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"22","author":"Combes","year":"1995","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2018.03.007_bib42","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1053\/gast.1996.v110.pm8613058","article-title":"Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis","volume":"110","author":"Lindor","year":"1996","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.cld.2018.03.007_bib43","first-page":"2314","article-title":"Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis","volume":"91","author":"Batts","year":"1996","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2018.03.007_bib44","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2018.03.007_bib45","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/00365529709000190","article-title":"Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study","volume":"32","author":"Eriksson","year":"1997","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"10.1016\/j.cld.2018.03.007_bib46","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4065\/72.12.1137","article-title":"Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis","volume":"72","author":"Lindor","year":"1997","journal-title":"Mayo Clin Proc."},{"issue":"3","key":"10.1016\/j.cld.2018.03.007_bib47","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.510290301","article-title":"Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis","volume":"29","author":"Angulo","year":"1999","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2018.03.007_bib48","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis","volume":"32","author":"Corpechot","year":"2000","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2018.03.007_bib49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0168-8278(03)00192-2","article-title":"Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis","volume":"39","author":"Poupon","year":"2003","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2018.03.007_bib50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2018.03.007_bib51","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1478-3231.2011.02678.x","article-title":"Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis","volume":"32","author":"Momah","year":"2012","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.cld.2018.03.007_bib52","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2018.03.007_bib53","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.cld.2018.03.007_bib54","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2018.03.007_bib55","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s00535-009-0051-9","article-title":"Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis","volume":"44","author":"Azemoto","year":"2009","journal-title":"J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2018.03.007_bib56","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326118300321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326118300321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T10:27:44Z","timestamp":1571567264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326118300321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1089326118300321"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2018.03.007","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2018.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}